A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4317-4325

  Pepic I ^a   Hafner, A ^a   Lovric J ^a   Pirkic B ^b   Filipovic Grcic J ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Absorption enhancer; Chitosan; Clinical tolerance; Dexamethasone; Micelles; Nanotechnology; Ocular bioavailability; Polymeric drug delivery systems; Triblock copolymers

Indexed keywords

CHITOSAN; DEXAMETHASONE; EYE DROPS; NONIONIC SURFACTANT; POLOXAMER;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CELL STRAIN CACO 2; COLLOID; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN TISSUE; HYDRODYNAMICS; HYDROPHOBICITY; IN VITRO STUDY; MEMBRANE TRANSPORT; MICELLE; MONOLAYER CULTURE; NANOTECHNOLOGY; SUSPENSION; ZETA POTENTIAL;

EID: 77957328525     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22137     Document Type: Article

References (39)

1. Nanjawade BK, Manvi FV, Manjappa AS. 2007. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 122:119-134.
2. Anumolu SS, Singh Y, Gao D, Stein S, Sinko PJ. 2009. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release 137:152-159.
3. Ludwig A. 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 57:1595-1639.
4. Shen J, Wang Y, Ping Q, Xiao Y, Huang X. 2009. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 137:217-223.
5. Barbault-Foucher S, Gref R, Russo P, Guechot J, Bochot A. 2002. Design of poly-epsilon-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J Control Release 83:365-375.
6. Diebold Y, Jarrin M, Saez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ. 2007. Ocular drug delivery by liposomechitosan nanoparticle complexes (LCS-NP). Biomaterials 28: 1553-1564.
7. Baeyens V, Felt-Baeyens O, Rougier S, Pheulpin S, Boisrame B, Gurny R. 2002. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI) for the treatment of external ocular infections in dogs. J Control Release 85:163-168.
8. Sasaki H, Nagano T, Sakanaka K, Kawakami S, Nishida K, Nakamura J, Ichikawa N, Iwashita J, Nakamura T, Nakashima M. 2003. One-side-coated insert as a unique ophthalmic drug delivery system. J Control Release 92:241-247.
9. Alvarez-Lorenzo C, Yanez F, Barreiro-Iglesias R, Concheiro A. 2006. Imprinted soft contact lenses as norfloxacin delivery systems. J Control Release 113:236-244.
10. Kapoor Y, Thomas JC, Tan G, John VT, Chauhan A. 2009. Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs. Biomaterials 30:867-878.
11. Ali M, Horikawa S, Venkatesh S, Saha J, Hong JW, Byrne ME. 2007. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J Control Release 124:154-162.
12. Ali Y, Lehmussaari K. 2006. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 58:1258-1268.
13. st ed. London: World Scientific-Imperial College Press. pp 649-673.
14. Lang JC. 1995. Ocular drug delivery - Conventional ocular formations. Adv Drug Deliv Rev 16:39-43.
15. Jiao J. 2008. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev 60:1663-1673.
16. Alexandridis P, Hatton TA. 1995. Poly(ethylene oxide)-poly(-propylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: Thermodynamics, structure, dynamics, and modelling. Colloids Surf A 96:1-46.
17. Chetoni P, Panichi L, Burgalassi S, Benelli U, Saettone MF. 2000. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J Ocul Pharmacol Ther 16:363-372.
18. Pepić I, Jalšenjak N, Jalšenjak I. 2004. Micellar solutions of triblock copolymer surfactants with pilocarpine. Int J Pharm 272:57-64.
19. Liaw J, Chang SF, Hsiao FC. 2001. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. Gene Ther 8:999-1004.
20. Smith J, Wood E, Dornish M. 2004. Effect of chitosan on epithelial cell tight junctions. Pharm Res 21:43-49.
21. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331.
22. Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC, Junginger HE. 1997. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 14:1197-1202.
23. Pepić I, Filipović-Grčić J, Jalšenjak I. 2008. Interactions in a nonionic surfactant and chitosan mixtures. Colloids Surf A 327:95-102.
24. Pepić I, Filipović-Grčić J, Jalšenjak I. 2009. Bulk properties of nonionic surfactant and chitosan mixtures. Colloids Surf A 336:135-141.
25. Beck RC, Pohlmann AR, Hoffmeister C, Gallas MR, Collnot E, Schaefer UF, Guterres SS, Lehr CM. 2007. Dexamethasone-loaded nanoparticle-coated microparticles: Correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. Eur J Pharm Biopharm 67:18-30.
26. Rowland JM, Sawyer WK, Tittel J, Ford CJ. 1986. Studies on the circadian rhythm of IOP in rabbits: Correlation with aqueous inflow and cAMP content. Curr Eye Res 5:201-206.
27. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. 2007. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126-133.
28. Wilhelmus KR. 2001. The Draize eye test. Surv Ophthalmol 45:493-515.
29. Kim DH, Martin DC. 2006. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 27:3031-3037.
30. Park TG, Yoo HS. 2006. Dexamethasone nano-aggregates composed of PEG-PLA-PEG triblock copolymers for antiproliferation of smooth muscle cells. Int J Pharm 326:169-173.
31. Smith JM, Dornish M, Wood EJ. 2005. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 26:3269-3276.
32. Bu HZ, Gukasyan HJ, Goulet L, Lou XJ, Xiang C, Koudriakova T. 2007. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 8:91-107.
33. De TK, Rodman DJ, Holm BA, Prasad PN, Bergey EJ. 2003. Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J Microencapsul 20:361-374.
34. Desai SD, Blanchard J. 1998. Evaluation of pluronic F127- based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 87:1190-1195.
35. Kaur IP, Garg A, Singla AK, Aggarwal D. 2004. Vesicular systems in ocular drug delivery: An overview. Int J Pharm 269:1-14.
36. Zambito Y, Zaino C, Di Colo G. 2006. Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport. Eur J Pharm Biopharm 64:16-25.
37. de la Fuente M, Seijo B, Alonso MJ. 2008. Bioadhesive hyaluronan- chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 15:668-676.
38. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. 2009. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 379:131-138.
39. De Campos AM, Sanchez A, Gref R, Calvo P, Alonso MJ. 2003. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 20:73-81.